Form 4: Bolt Biotherapeutics' Chief Medical Officer Acquires 235,000 Stock Options

Edith A. Perez, Chief Medical Officer of Bolt Biotherapeutics, acquired 235,000 stock options on March 4, 2024, according to a recent SEC filing.

Summary

• Edith A. Perez, the Chief Medical Officer of Bolt Biotherapeutics, Inc., filed a Form 4 with the SEC on March 6, 2024.
• The filing reports a transaction that occurred on March 4, 2024, where Ms. Perez acquired 235,000 stock options.
• These options have an exercise price of $1.27 and expire on March 3, 2034.
• The options vest monthly, with 1/36th of the shares vesting each month following January 1, 2024, contingent upon continuous service to the Issuer.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine SEC filing regarding stock option grants. It suggests confidence from the executive but doesn't provide strong positive or negative signals.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule implies continued service from the Chief Medical Officer.

Industry Context

This is a standard SEC filing related to executive compensation. Stock options are a common form of compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options to incentivize their executives.
• The vesting schedule of 1/36th per month is a fairly standard vesting schedule.

Stakeholder Impact

• The granting of stock options aligns the interests of the Chief Medical Officer with those of the shareholders, incentivizing her to contribute to the company's success.

Key Dates